NexLife, a physician-led telehealth platform, announced expanded compounded GLP-1 programs with flat-rate pricing that remains constant across all dose levels, ranging from $119-$169 monthly depending on medication and plan length. The service includes $377 in bundled nutrition, coaching, and provider support at no additional cost, independent batch testing, and expedited delivery.

The FDA has approved Eli Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in high-risk adults with type 2 diabetes. In a 13,299-patient study, Mounjaro showed an 8% lower MACE-3 rate than Trulicity, meeting non-inferiority objectives. With $18.6B in first-half 2026 sales, this expanded indication could drive further growth and narrow the competitive gap with Novo Nordisk's Ozempic.

Novo Nordisk, which pioneered GLP-1 weight-loss drugs but lost market leadership to Eli Lilly, is attempting a comeback through product innovation. The company has launched a pill version of Wegovy and partnered with Vivani Medical to develop an implant that could deliver the drug once or twice yearly, potentially revolutionizing convenience in the GLP-1 market. While Eli Lilly maintains a stronger market position and higher valuation, Novo Nordisk's continued innovation could help it regain competitive ground.

The article highlights CVS Health and Roche as two stocks positioned to benefit from the growing GLP-1 drug market. CVS is leveraging its pharmacy network and low-cost telemedicine services to improve patient access to GLP-1 medications, while Roche is developing promising weight-loss drugs including CT-388, a dual GLP-1/GIP agonist showing strong clinical results. Both companies offer diversified business models beyond GLP-1 to mitigate risks.

Hematologists increasingly favor a diverse sickle cell disease treatment landscape combining gene therapies with oral disease-modifying agents. Mitapivat (Agios) surged to the most desired pipeline therapy at 24% physician preference, while BEAM-101 (Beam Therapeutics) and etavopivat (Novo Nordisk) also gained traction. Despite innovation, 70% of hematologists rate unmet need as high, with 51% of SCD patients not optimally managed with current treatments.

Europe's oral anti-diabetic drug market is projected to grow from USD 7.86 billion in 2026 to USD 9.2 billion by 2031 at a 3.22% CAGR, driven by rising type 2 diabetes and obesity rates, aging populations, and cardio-renal benefits of SGLT-2 inhibitors. However, high treatment costs and reimbursement restrictions remain significant barriers to market expansion.

The global semaglutide market is projected to grow from USD 31.97 billion in 2026 to USD 58.72 billion by 2031, driven by rising obesity and diabetes prevalence, expanded cardiovascular approvals, and increased adoption of oral and self-injectable formulations. However, high treatment costs, reimbursement barriers, and supply constraints remain significant challenges. Ozempic leads the market with 65.31% share, while Wegovy is experiencing rapid growth. Asia-Pacific is emerging as the fastest-growing region at 17.12% CAGR.

Eli Lilly's weight-loss pill Foundayo received U.K. approval, marking Europe's first GLP-1 oral medication authorization. The drug offers advantages over competitor Novo Nordisk's Wegovy with no food restrictions. The global obesity drug market is projected to grow from $66 billion in 2025 to $92-200 billion by 2027, presenting significant growth opportunities for multiple manufacturers.

Eli Lilly announced it will file for FDA approval of retatrutide, its next-generation weight-loss drug, in Q1 2027. The drug demonstrated 28.3% average weight loss over 80 weeks in phase 3 trials, outperforming competitors like Novo Nordisk's Wegovy. With strong Q2 financial results (48% revenue growth) and potential applications beyond obesity, Eli Lilly is positioned to expand its market lead.

Pfizer is developing berobenatide, a monthly injectable weight-loss drug that could compete with market leaders Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Phase 2b data shows 16% weight loss in 32 weeks with no plateau, positioning it as potentially competitive despite lower efficacy than rivals. The anti-obesity market is projected to reach $190 billion by 2035, offering significant opportunity, though Pfizer faces risks from patent cliffs, increased competition from companies like Amgen, and regulatory hurdles.

Viking Therapeutics stock fell 18.6% in July as investors focused on the company's cash burn ($96M quarterly) and potential shareholder dilution from a planned $500M equity offering, despite positive progress on its phase 3 trials for weight-loss drug VK2735. The company has sufficient cash through 2028 and expects trial results by then, maintaining long-term potential in the weight-loss drug market.

Novo Nordisk announced that board members and executives received 74 shares each on August 5, 2026, through the company's Restricted Shares programme for the 100th Anniversary. The company also won a Dutch court injunction protecting patients from unapproved compounded semaglutide nasal spray, reinforcing patient safety and intellectual property rights. Additionally, Novo Nordisk reported adjusted operating profit of DKK 33,389 million for Q2 2026 and raised its full-year outlook.